This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
7axr
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Crystal structure of BRD4(1) bound to the dual BET-HDAC inhibitor LSH24== | ==Crystal structure of BRD4(1) bound to the dual BET-HDAC inhibitor LSH24== | ||
| - | <StructureSection load='7axr' size='340' side='right'caption='[[7axr]]' scene=''> | + | <StructureSection load='7axr' size='340' side='right'caption='[[7axr]], [[Resolution|resolution]] 1.50Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7AXR OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7AXR FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[7axr]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7AXR OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7AXR FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7axr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7axr OCA], [https://pdbe.org/7axr PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7axr RCSB], [https://www.ebi.ac.uk/pdbsum/7axr PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7axr ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=S7T:4-acetyl-3-ethyl-N-(3-(3-(hydroxyamino)-3-oxopropyl)phenyl)-5-methyl-1H-pyrrole-2-carboxamide'>S7T</scene></td></tr> |
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7axr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7axr OCA], [https://pdbe.org/7axr PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7axr RCSB], [https://www.ebi.ac.uk/pdbsum/7axr PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7axr ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | == Disease == | ||
| + | [[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Note=A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUT which produces a BRD4-NUT fusion protein.<ref>PMID:12543779</ref> <ref>PMID:11733348</ref> | ||
| + | == Function == | ||
| + | [[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Plays a role in a process governing chromosomal dynamics during mitosis (By similarity). | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Multitarget drugs are an emerging alternative to combination therapies. In three iterative cycles of design, synthesis, and biological evaluation, we developed a novel type of potent hybrid inhibitors of bromodomain, and extra-terminal (BET) proteins and histone deacetylases (HDACs) based on the BET inhibitor XD14 and well-established HDAC inhibitors. The most promising new hybrids, 49 and 61, displayed submicromolar inhibitory activity against HDAC1-3 and 6, and BRD4(1), and possess potent antileukemia activity. 49 induced apoptosis more effectively than the combination of ricolinostat and birabresib (1:1). The most balanced dual inhibitor, 61, induced significantly more apoptosis than the related control compounds 62 (no BRD4(1) affinity) and 63 (no HDAC inhibition) as well as the 1:1 combination of both. Additionally, 61 was well tolerated in an in vivo zebrafish toxicity model. Overall, our data suggest an advantage of dual HDAC/BET inhibitors over the combination of two single targeted compounds. | ||
| + | |||
| + | 4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.,Schaker-Hubner L, Warstat R, Ahlert H, Mishra P, Kraft FB, Schliehe-Diecks J, Scholer A, Borkhardt A, Breit B, Bhatia S, Hugle M, Gunther S, Hansen FK J Med Chem. 2021 Sep 28. doi: 10.1021/acs.jmedchem.1c01119. PMID:34582215<ref>PMID:34582215</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 7axr" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Huegle M]] | + | [[Category: Huegle, M]] |
| + | [[Category: Bd1]] | ||
| + | [[Category: Bet]] | ||
| + | [[Category: Beti]] | ||
| + | [[Category: Brd4]] | ||
| + | [[Category: Bromodomain]] | ||
| + | [[Category: Dual inhibitor]] | ||
| + | [[Category: First bromodomain]] | ||
| + | [[Category: Hdac]] | ||
| + | [[Category: Hdaci]] | ||
| + | [[Category: Lsh24]] | ||
| + | [[Category: Protein binding]] | ||
Revision as of 12:48, 13 October 2021
Crystal structure of BRD4(1) bound to the dual BET-HDAC inhibitor LSH24
| |||||||||||
Categories: Large Structures | Huegle, M | Bd1 | Bet | Beti | Brd4 | Bromodomain | Dual inhibitor | First bromodomain | Hdac | Hdaci | Lsh24 | Protein binding
